NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Natco Pharma FY26 PAT at INR 1,418.5 Cr; Guides for Muted INR 700-750 Cr PAT in FY27
Natco Pharma reported a decline in FY26 performance with consolidated revenue of INR 4,375.9 crores and PAT of INR 1,418.5 crores, primarily due to the tapering impact of Revlimid. The company provided a cautious guidance for FY27, expecting a PAT of INR 700-750 crores as it transitions through a base year without major exclusivities. However, management remains optimistic about FY28 onwards, targeting 15-25% compounding growth driven by a strong pipeline in the US, Brazil, and Canada. The company maintains a strong cash position of INR 2,400 crores, which it plans to deploy for potential M&A activities.
முக்கிய அம்சங்கள்
FY26 consolidated revenue decreased to INR 4,375.9 crores from INR 4,784 crores in the previous year.Management guided for a significantly lower FY27 PAT of INR 700-750 crores on revenues of INR 3,400-3,500 crores.Net cash on the balance sheet stands at approximately INR 2,400 crores, earmarked for 1-2 large acquisitions.Growth is expected to rebound from FY28 with 15-25% CAGR driven by new product exclusivities.Q4 FY26 PAT included a one-time tax benefit of INR 115 crores due to the shift to a new tax regime.
👀 கவனிக்க வேண்டியவை
Investors should prepare for a muted FY27 as the company resets its earnings base following the Revlimid windfall. The primary triggers to watch are the deployment of the INR 2,400 crore cash reserve for M&A and the launch of new exclusivities starting FY28.
Natco Pharma and Lupin Receive U.S. FDA Approval for Eribulin Mesylate Injection
Natco Pharma, in alliance with Lupin Limited, has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection. The product is a generic version of Eisai's Halaven, indicated for metastatic breast cancer and liposarcoma. The reference drug had estimated annual sales of USD 43.7 million in the U.S. as of April 2026. This approval aligns with Natco's strategy of focusing on limited competition molecules in the U.S. oncology market.
முக்கிய அம்சங்கள்
U.S. FDA approval received for Eribulin Mesylate Injection (1 mg/2ml) Single-Dose Vials.Product is bioequivalent to the reference drug Halaven® by Eisai, Inc.Target market size for the drug is estimated at USD 43.7 million in annual U.S. sales.The approval was achieved through an alliance partnership with Lupin Limited.Indicated for the treatment of metastatic breast cancer and unresectable liposarcoma.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that strengthens Natco's niche oncology portfolio. Monitor the commercial launch timeline and the revenue contribution from this product in upcoming quarterly results.
Natco Pharma FY26 Revenue Declines 8.5% to ₹43,759 Mn; EBITDA Margins Contract to 39.6%
Natco Pharma reported a challenging FY26 with consolidated revenue falling 8.5% YoY to ₹43,759 million and PAT declining to ₹14,185 million. The Q4FY26 performance was particularly weak with revenue dropping 36.5% YoY to ₹8,169 million, though PAT was bolstered by a one-time tax benefit of ₹1,150 million from moving to a new tax regime. Despite the financial slowdown, the company completed a strategic 35.75% stake acquisition in Adcock Ingram (South Africa) and launched high-potential products like Semaglutide in India. The export formulation business, a key driver, saw a significant revenue dip from ₹37,597 million to ₹32,345 million for the full year.
முக்கிய அம்சங்கள்
Full-year FY26 consolidated revenue stood at ₹43,759 million, down from ₹47,840 million in FY25.EBITDA margins saw a sharp contraction to 39.6% in FY26 compared to 53.3% in the previous year.Q4FY26 PAT of ₹2,690 million includes a one-time deferred tax asset remeasurement benefit of ₹1,150 million.Completed strategic acquisition of a 35.75% stake in South African firm Adcock Ingram Holdings Limited.Maintains a robust US pipeline with 28 approved Para IVs and 17 Solo First-to-File (FTF) products pending.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of margin compression and the decline in export formulation revenue, which are key concerns. The long-term outlook depends on the successful scaling of the Semaglutide launch and the realization of synergies from the Adcock Ingram acquisition.
Natco Pharma FY26 Results: Subsidiaries Contribute INR 1,365 Million to Net Profit
Natco Pharma Limited has released its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified audit opinion. The consolidated performance was significantly supported by its 13 subsidiaries, which generated a combined revenue of INR 7,110 million and a net profit of INR 1,365 million. Additionally, the company's new associate, Adcock Ingram Holdings in South Africa, contributed INR 466 million to the group's net profit. The company also expanded its footprint by incorporating NATCO Crop Health Sciences and a new South African subsidiary during the year.
முக்கிய அம்சங்கள்
Thirteen subsidiaries contributed INR 7,110 million in revenue and INR 1,365 million in net profit for FY26.Group's share of profit from new associate Adcock Ingram Holdings Limited stood at INR 466 million.Total assets of subsidiaries before consolidation adjustments reached INR 35,047 million.Incorporated new entities including NATCO Pharma South Africa and NATCO Crop Health Sciences during the fiscal year.The Board approved updated CSR and Fair Disclosure policies alongside the annual financial results.
👀 கவனிக்க வேண்டியவை
Investors should focus on the growing contribution from international subsidiaries and the new crop health division as potential long-term growth drivers. The profit contribution from the South African associate indicates successful inorganic expansion that warrants continued monitoring.
Natco Pharma Shareholders Approve Re-appointment of Top Management with Over 98% Majority
Natco Pharma shareholders have overwhelmingly approved the re-appointment of the company's core leadership team, including the Chairman and CEO, effective April 1, 2026. The resolutions were passed via postal ballot with approval rates ranging from 98.74% to 99.40%. A total of 111.34 million votes were polled, representing approximately 62.17% of the total shareholding. This result ensures management continuity and stability for the company's long-term strategic goals.
முக்கிய அம்சங்கள்
Sri V.C. Nannapaneni re-appointed as Chairman & Managing Director with 98.74% votes in favorSri Rajeev Nannapaneni re-appointed as Vice Chairman & CEO with 99.28% approvalTotal voter turnout recorded at 111.34 million shares, representing 62.17% of the company's equityInstitutional holders supported the CMD re-appointment with 94.06% in favor, despite 5.94% voting againstAll four special resolutions for executive director re-appointments were passed with the requisite majority
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the leadership continuity at Natco Pharma, as the core management team responsible for previous growth remains in place. No immediate portfolio changes are necessary based on this routine but important governance update.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Natco Pharma Approves Demerger of Agrochemicals Business; 1:1 Share Entitlement Ratio
Natco Pharma has approved the demerger of its Agrochemicals division into a separate listed entity, Natco Crop Health Sciences Limited. Shareholders will receive one share of the new company for every one share held in Natco Pharma, resulting in an 80% direct ownership stake for existing shareholders. The Agrochemicals division is currently a small part of the business, contributing ₹60.62 crore (1.48%) to the total turnover in FY25. The company also announced a new $100,000 investment in Nigeria and the liquidation of its non-viable Australian subsidiary.
முக்கிய அம்சங்கள்
Demerger of Agrochemicals business into Natco Crop Health Sciences Limited with a 1:1 share ratio.Agrochemicals division turnover was ₹60.62 crore in FY25, representing 1.48% of total revenue.Post-demerger, shareholders will hold 80% direct stake and 20% indirect stake via Natco Pharma in the new entity.Incorporation of a new wholly owned subsidiary in Nigeria with an investment up to $100,000.Liquidation of Australian subsidiary Natco Pharma Australia Pty Ltd expected by September 2026.
👀 கவனிக்க வேண்டியவை
Investors should welcome this move as it aims to unlock value and provide a focused growth platform for the agrochemical business. No immediate action is needed as the demerger process involves multiple regulatory approvals and has an appointed date of October 1, 2026.
Natco Pharma Launches Generic Semaglutide in India at MRP Starting INR 1,290
Natco Pharma has announced the launch of generic Semaglutide injection in India, timed precisely with the patent expiry. The company is the first to introduce this GLP-1 therapy in multi-dose vials, priced aggressively at an MRP starting from INR 1,290, which is approximately 90% cheaper than the innovator's brand. This move aims to significantly increase patient accessibility for Type 2 diabetes treatment. Additionally, Natco plans to launch a pen device variant in April 2026, priced between INR 4,000 and INR 4,500.
முக்கிய அம்சங்கள்
Launch of generic Semaglutide (SEMANAT™ and SEMAFULL™) on Day 1 of patent expiry.Pricing for multi-dose vials starts at INR 1,290, representing a 90% discount to the innovator brand.Pen device launch scheduled for April 2026 with MRP ranging from INR 4,000 to INR 4,500.First company to offer generic Semaglutide in vial dosage form in the Indian market.Strategic move to offer the product to third parties for co-marketing to enhance market penetration.
👀 கவனிக்க வேண்டியவை
Investors should monitor the sales trajectory of this blockbuster molecule as Natco's aggressive pricing could lead to significant market share gains in the Indian diabetes segment. This launch reinforces Natco's strategy of being a first-mover in high-value generic opportunities.
Natco Pharma Launches Generic Pomalyst in U.S. with 180-Day Shared Exclusivity
Natco Pharma, in partnership with Breckenridge Pharmaceutical, has launched Pomalidomide Capsules, a generic version of Celgene's Pomalyst, in the U.S. market. The product addresses a significant market, with Pomalyst recording estimated U.S. sales of USD 3.2 billion for the 12 months ending September 2025. Natco expects to benefit from 180 days of shared exclusivity, which usually provides a period of higher pricing and limited competition. This launch significantly strengthens Natco's oncology and specialty portfolio in its most critical export market.
முக்கிய அம்சங்கள்
Launched generic Pomalidomide Capsules in 1mg, 2mg, 3mg, and 4mg strengths in the U.S. market.Targets a multi-billion dollar market with Pomalyst U.S. sales estimated at USD 3.2 billion annually.Entitled to 180 days of shared exclusivity, providing a competitive advantage and margin protection.Indicated for adult patients with multiple myeloma and Kaposi sarcoma, distributed via specialty pharmacies.
👀 கவனிக்க வேண்டியவை
This is a high-impact launch that should significantly bolster Natco's U.S. revenues and margins over the next two quarters. Investors should maintain a positive outlook while monitoring the ramp-up in market share during the exclusivity period.
Natco Pharma Confirms Semaglutide Partnership with Eris Lifesciences for March 2026 Launch
Natco Pharma has confirmed its partnership with Eris Lifesciences for the marketing of the weight-loss drug Semaglutide in India. The company received CDSCO approval for the drug on February 14, 2026, and is preparing for a commercial launch in March 2026. While the company stated the partnership is in the ordinary course of business with no immediate material financial impact, it marks a significant entry into the high-growth GLP-1 segment. Natco is currently working with multiple marketing partners to facilitate this upcoming domestic launch.
முக்கிய அம்சங்கள்
Received CDSCO approval for Semaglutide in India on February 14, 2026Confirmed marketing partnership with Eris Lifesciences for the weight-loss drugProduct launch in the Indian market scheduled for March 2026Company clarified that negotiations are part of ordinary business operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from the Semaglutide launch starting Q1 FY27, as this segment represents a major growth opportunity. The ability to scale through multiple marketing partners like Eris could provide a competitive edge in the domestic market.
Natco Pharma Proposes Reappointment of CMD and CEO with Salary Caps up to ₹1.95 Crore
Natco Pharma is seeking shareholder approval via postal ballot for the reappointment of four key executive directors for a one-year term starting April 2026. The proposal includes Chairman V.C. Nannapaneni with a salary cap of ₹1.95 crore and CEO Rajeev Nannapaneni at ₹1.80 crore, both eligible for a 1% profit commission. Additionally, two other senior directors are proposed for reappointment with salaries up to ₹1.93 crore each. This move ensures leadership stability for the upcoming fiscal year while maintaining performance-linked incentives.
முக்கிய அம்சங்கள்
Proposed reappointment of CMD V.C. Nannapaneni for 1 year with ₹1.95 crore salary plus 1% profit commissionProposed reappointment of CEO Rajeev Nannapaneni for 1 year with ₹1.80 crore salary plus 1% profit commissionDirectors P.S.R.K. Prasad and Dr. D. Linga Rao proposed for 1-year terms with salaries up to ₹1.93 crore eachShareholder e-voting period scheduled from February 23, 2026, to March 24, 2026Remuneration includes special incentives ranging from 20% to 100% of salary depending on the role
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to ensure leadership continuity; the short one-year tenure suggests a near-term review of leadership roles or potential succession planning.
Natco Pharma Q3 PAT at ₹151.3 Cr; Zero Revlimid Revenue; Eyes Large M&A with ₹2,500 Cr Cash
Natco Pharma reported a consolidated revenue of ₹705.4 crores for Q3 FY26, showing resilience despite zero revenue contribution from Revlimid during the quarter. The company is successfully pivoting towards emerging markets like Brazil and Canada while integrating its 35.75% stake in Adcock Ingram, which is expected to contribute ₹35-40 crores to quarterly PAT. Management is actively pursuing 1-2 large acquisitions using its ₹2,500 crore cash reserve and expects GLP-1 (Semaglutide) approval for the Indian market shortly. Additionally, the de-merger of the Crop Health Sciences business is on track for completion within the next 8-9 months.
முக்கிய அம்சங்கள்
Consolidated revenue grew to ₹705.4 crores in Q3 FY26 compared to ₹651.1 crores in the previous year.Maintained an EBITDA margin of 30.7% with a net profit of ₹151.3 crores despite zero Revlimid contribution.Adcock Ingram acquisition expected to add approximately ₹35-40 crores to quarterly PAT moving forward.Company holds a net cash position of ₹2,500 crores, earmarked for 1-2 large-scale acquisitions in 2026.GLP-1 (Semaglutide) launch in India is imminent following expected DCGI approval and a fill-finish tie-up with OneSource.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Crop Health de-merger and the upcoming GLP-1 launch in India as key growth catalysts. The successful transition from Revlimid dependency to a diversified emerging market model strengthens the long-term investment case.
Natco Pharma Receives CDSCO Approval for Generic Semaglutide Injection in India
Natco Pharma has received regulatory approval from the CDSCO to manufacture and market generic Semaglutide injection in India. The drug is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the product in the domestic market in March 2026. This approval allows Natco to enter the high-demand GLP-1 receptor agonist segment, diversifying its portfolio beyond its traditional strength in oncology.
முக்கிய அம்சங்கள்
Received CDSCO approval to manufacture and market generic Semaglutide injection in IndiaCommercial launch scheduled for the Indian market in March 2026Product targets the treatment of type 2 diabetes mellitus as an adjunct to diet and exerciseLeverages Natco's existing infrastructure of 9 manufacturing sites and 2 R&D facilities
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant portfolio expansion into the chronic care segment. Monitor the company's pricing strategy and market penetration following the March 2026 launch.
Natco Pharma Receives USFDA EIR with VAI Status for Chennai API Unit
Natco Pharma has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Manali, Chennai. The inspection, which took place from November 17 to November 21, 2025, had originally resulted in seven Form-483 observations. The USFDA has now classified the inspection as Voluntary Action Indicated (VAI), meaning the facility is considered to be in a state of compliance. This resolution is a significant positive as it clears the path for future product approvals from this site.
முக்கிய அம்சங்கள்
Received Establishment Inspection Report (EIR) for the Chennai API unit from the USFDA.The inspection conducted in November 2025 resulted in 7 observations in Form-483.USFDA has officially classified the inspection status as Voluntary Action Indicated (VAI).The VAI status confirms that the facility meets regulatory standards despite the initial observations.Clears regulatory hurdles for the API division which supports the company's oncology and specialty generic portfolio.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that mitigates regulatory risk for Natco's API supply chain. The stock may see a positive reaction as the VAI status allows for uninterrupted business and new product approvals from the Chennai site.
Natco Pharma Declares 3rd Interim Dividend of Rs 1.50 per Share; Record Date Feb 18
Natco Pharma Limited has declared its third interim dividend of Rs 1.50 per equity share for the financial year 2025-26. This dividend represents a 75% payout on the face value of Rs 2 per share. The company has fixed February 18, 2026, as the record date to identify eligible shareholders for this payout. The distribution of the dividend is scheduled to begin on February 26, 2026.
முக்கிய அம்சங்கள்
3rd interim dividend of Rs 1.50 per equity share (75% of face value) declared for FY 2025-26Record date for dividend eligibility is set for February 18, 2026Dividend payment process will commence from February 26, 2026Announcement follows the Board of Directors meeting held on February 12, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend must own the shares before the ex-dividend date. Existing shareholders should verify their bank details are updated for seamless credit.
Natco Pharma Q3 PAT Up 14% YoY to ₹1,513M; Declares ₹1.50 Dividend & Chile Expansion
Natco Pharma reported a 14% YoY increase in consolidated net profit to ₹1,513 million for Q3 FY26, despite a significant sequential decline from Q2. The company declared a third interim dividend of ₹1.50 per share and announced the incorporation of a new subsidiary in Chile. A major milestone was the completion of the 35.75% stake acquisition in South Africa's Adcock Ingram for approximately $225 million. Additionally, the company is evaluating a demerger of its Agro Chemicals business and has appointed Amit Parekh as the new CFO.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations grew 36% YoY to ₹6,473 million, though down from ₹13,630 million in Q2.Declared third interim dividend of ₹1.50 per share (75% of face value) with record date of Feb 18, 2026.Completed acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for ZAR 3,873 million (~$225 million).Approved incorporation of a wholly-owned subsidiary in Chile with an investment of up to $300,000.Appointed Amit Parekh as CFO effective Feb 13, 2026, following the superannuation of S.V.V.N. Appa Rao.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of the Adcock Ingram acquisition and the potential value unlocking from the proposed Agro Chemicals demerger. While YoY growth is positive, the high sequential volatility in earnings warrants a cautious approach to quarterly performance expectations.
Natco Pharma Appoints Amit Parekh as CFO and Kalakuntla Srinivas Rao as EVP Pharma Division
Natco Pharma has announced a leadership transition following the superannuation of its current CFO, Mr. S.V.V.N. Appa Rao, effective February 12, 2026. Mr. Amit Parekh, currently EVP of Finance and Accounts with 23+ years of experience including a tenure at Dr. Reddy's, will take over as CFO on February 13, 2026. Furthermore, the company has appointed Mr. Kalakuntla Srinivas Rao as EVP of the Pharma Division, bringing over 25 years of experience from MSN Laboratories and Lupin. These moves indicate a structured succession plan and a focus on strengthening operational leadership.
முக்கிய அம்சங்கள்
Mr. S.V.V.N. Appa Rao to retire as CFO on February 12, 2026, after reaching superannuation.Mr. Amit Parekh, with 23+ years of experience in finance and M&A, appointed as the new CFO effective February 13, 2026.Mr. Kalakuntla Srinivas Rao appointed as EVP - Pharma Division with 25+ years of experience in USFDA and cGMP compliance.New CFO Amit Parekh previously held senior finance roles at Dr. Reddy’s Laboratories and has expertise in IFRS and US GAAP.EVP Kalakuntla Srinivas Rao has a proven track record in managing formulation operations and facility design.
👀 கவனிக்க வேண்டியவை
This is a planned leadership transition and should be viewed as a routine corporate development. Investors should monitor if the new leadership introduces any shifts in financial strategy or operational focus in the coming years.
Natco Pharma Q3 FY26 Net Profit Rises 14% to INR 1,513 Mn; Revenue Up 8% YoY
Natco Pharma reported a consolidated revenue of INR 7,054 Mn for Q3 FY26, an 8.3% increase over the previous year. Net profit grew 14.3% YoY to INR 1,513 Mn, aided by the strategic acquisition of a 35.75% stake in South Africa's Adcock Ingram. Export formulations continue to be the backbone of the business, contributing nearly 76% of the quarterly revenue. The company is also advancing its pipeline with 30 approved Para IVs and significant R&D investments in cell and gene therapy.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue reached INR 7,054 Mn compared to INR 6,511 Mn in Q3 FY25.Net Profit stood at INR 1,513 Mn with an EPS of INR 8.46 for the quarter.Export Formulations revenue grew to INR 4,214 Mn, representing 75.7% of total revenue.Integration of Adcock Ingram (South Africa) contributed INR 109 Mn to the bottom line after amortization.Robust pipeline includes 14 Solo FTFs and 30 approved Para IV products for the US market.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook given the strong 9-month performance (EPS of INR 64.24) and the potential of the US pipeline. Monitor the scaling of the Crop Health Sciences segment and the long-term impact of the South African acquisition.
Natco Pharma Receives Tentative US FDA Approval for Generic Balversa; $60M Market Opportunity
Natco Pharma has received tentative approval from the U.S. FDA for Erdafitinib tablets, which is a generic version of Janssen Biotech's Balversa. The drug is used to treat adult patients with specific types of metastatic urothelial carcinoma. For the 12-month period ending September 2025, the reference drug had estimated sales of approximately $60 million in the U.S. market. This development is consistent with Natco's strategy of focusing on niche oncology products with limited competition in the United States.
முக்கிய அம்சங்கள்
Received tentative U.S. FDA approval for Erdafitinib tablets in 3mg, 4mg, and 5mg strengths.Generic version of Balversa, targeting locally advanced or metastatic urothelial carcinoma.Reference drug annual U.S. sales estimated at $60 million as of September 2025.Strengthens Natco's position as a leading oncology player in the U.S. generics market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive addition to Natco's U.S. pipeline, though the immediate financial impact is limited by the 'tentative' nature of the approval. Monitor for the transition to final approval and the subsequent commercial launch timeline.
Natco Pharma Acquires Remaining 49% Stake in Indonesian Subsidiary for ₹7.7 Crores
Natco Pharma's Singapore-based subsidiary has acquired the remaining 49% stake in PT NATCO Lotus Farma, making it a 100% owned entity. The acquisition was completed for a cash consideration of approximately ₹7.7 crores (IDR 14.07 billion). The Indonesian subsidiary reported a turnover of ₹2.7 crores for the period ending September 2025, showing growth from previous years. This consolidation allows Natco full control over its operations and expansion strategy in the Indonesian pharmaceutical market.
முக்கிய அம்சங்கள்
Acquired 49% stake in PT NATCO Lotus Farma to reach 100% total ownershipTotal cash consideration for the stake is approximately ₹7.7 crores (IDR 14.07 billion)Target entity turnover increased to ₹2.7 crores for YTD Sep 2025 from ₹1.6 crores in FY25The acquisition was completed at a par value of IDR 100,000 per share
👀 கவனிக்க வேண்டியவை
This is a small-scale strategic consolidation that simplifies the corporate structure in Indonesia. Investors should monitor the growth of the Indonesian business as it scales from a low base.
Natco Pharma Clarifies Ongoing Patent Litigation Against Novo Nordisk
Natco Pharma has provided a clarification to the National Stock Exchange regarding news reports of its plea to revoke a patent held by Novo Nordisk. The company confirmed that the litigation has been ongoing for several months and is currently awaiting a final judicial outcome. Management stated that there is no material financial impact on the company at this stage. Natco has committed to informing the exchanges once a final decision is reached if it significantly impacts financial performance.
முக்கிய அம்சங்கள்
Natco Pharma is seeking the revocation of a patent held by Novo Nordisk in the High Court.The legal proceedings have been active for several months without a final verdict reached as of January 7, 2026.The company currently reports no material financial impact resulting from the news article or the ongoing case.Management maintains that all necessary disclosures under Regulation 30 of SEBI LODR are being followed.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final outcome of this patent challenge as a victory could allow Natco to launch generic versions of the drug, though no immediate financial impact is expected.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
